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Prion diseases are neurodegenerative disorders caused by the accumulation of abnormal
prion protein (PrPSc) in the central nervous system. With the aim of elucidating the mecha-
nism underlying the accumulation and degradation of PrPSc, we investigated the role of
autophagy in its degradation, using cultured cells stably infected with distinct prion strains.
The effects of pharmacological compounds that inhibit or stimulate the cellular signal trans-
duction pathways that mediate autophagy during PrPSc degradation were evaluated. The
accumulation of PrPSc in cells persistently infected with the prion strain Fukuoka-1 (FK),
derived from a patient with Gerstmann–Sträussler–Scheinker syndrome, was significantly
increased in cultures treated with the macroautophagy inhibitor 3-methyladenine (3MA) but
substantially reduced in those treated with the macroautophagy inducer rapamycin. The
decrease in FK-derived PrPSc levels was mediated, at least in part, by the phosphatidylino-
sitol 3-kinase/MEK signalling pathway. By contrast, neither rapamycin nor 3MA had any
apparently effect on PrPSc from either the 22L or the Chandler strain, indicating that the deg-
radation of PrPSc in host cells might be strain-dependent.
Introduction
Transmissible spongiform encephalopathies, so-called prion diseases, are fatal neurodegenera-
tive disorders that include Creutzfeldt–Jakob disease in humans, bovine spongiform encepha-
lopathy in cattle and scrapie in sheep. They are transmitted by prions, unconventional
infectious agents that mainly consist of proteinase-resistant and β-sheet-rich amyloidogenic
isoforms (PrPSc) of the normal host protein PrP (referred to as the conformational isoform,
PrPC) [1, 2].
The degradation of cellular organelles and cytoplasmic proteins is carried out by a process
referred to as autophagy, of which there are three types: macroautophagy, microautophagy and
chaperone-mediated autophagy (CMA). In macroautophagy, cytoplasmic proteins or
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components thereof are incorporated into autophagosome; these vesicles then fuse with lyso-
somes for subsequent degradation. Macrophagy is the typical cellular degradation pathway and
it differs from microautophagy, in which proteins are directly imported into lysosomes, and
CMA, in which chaperones recognizing characteristic protein motifs mediate lysosomal trans-
port. Thus, the term autophagy usually indicates macroautophagy [3]. Recently, autophagy
was shown to play a crucial role in the clearance of aggregated proteins, such as insoluble amy-
loid β-proteins, α-synuclein and huntingtin [3–13]. Related studies have focused on the role of
the autophagic system in the degradation of PrPSc, with misfolded PrP shown to undergo deg-
radation in the autophagic system in vitro [14] and in vivo by mutated PrP (A116V) transgenic
mice [15] and 263K-infected hamsters [16]. In addition, PrPSc was shown to be remarkably
degraded by LiCl-induced autophagy, with different lithium compounds, such as Li2CO3, LiBr
and LiCH3COO, strongly provoking autophagy and thus reducing PrP
Sc levels in cells infected
with mouse strain RML prions [17, 18]. Trehalose, an α-linked disaccharide synthesised by
fungi, was shown to induce autophagy and to reduce PrPSc [19] as well as mutant huntingtin
and α-synuclein proteins [20]. Recently, we found that the immune suppressor FK506 (tacroli-
mus) prevented prion infection in vivo and promoted the degradation of PrPSc in vitro [21].
The mechanism seems to involve the accelerated clearance of PrPSc in prion-infected cells via
the activation of p62, a cytosolic protein known to mediate both the formation and the degra-
dation of abnormal protein aggregates [22]. Taken together, these observations suggest that
PrPSc produced in the cytoplasm of host cells might undergo autophagic degradation.
In this study, we focused on the cellular signalling cascades related to autophagy and com-
pared the effect of inhibitors/stimulators of this system on PrPSc degradation, using cell cul-
tures persistently infected with different strains of prions.
Materials and Methods
Reagents and Antibodies
Anti-PrP polyclonal antiserum (SS) and M20 (Santa Cruz Biotechnology, Dallas, TX, USA)
were mouse and goat polyclonal antibodies, respectively. Anti-PrP SAF61 (SPI-BIO/Cayman
Chemical, Ann Arbor, MI, USA), 3F4 (Signet Laboratories, Dedham, MA, USA) and mouse β-
actin (Sigma Aldrich, St. Louis, MO, USA) were mouse monoclonal antibodies. Anti-LC3
(Medical & Biological Laboratories, Japan), anti-Beclin-1 and anti- Atg12-Atg5 (both from
Cell Signaling Technology, Japan) were rabbit polyclonal antibodies used in the detection of
molecules involved in autophagy. The rabbit monoclonal and polyclonal antibodies anti-
Lamp1, anti-phosphorylated S6 ribosomal protein (Ser235/236), anti-phosphorylated eIF4B
(Ser422), anti-Akt, anti-phosphorylated Akt (Ser473), anti-p44/42 MAPK and anti-phosphory-
lated p44/42 MAPK (Thr202/204) were purchased from Cell Signaling Technology. Horserad-
ish-peroxidase-conjugated anti-mouse, anti-rabbit (GE Healthcare, Japan) and anti-goat
(Jackson ImmunoResearch Laboratories, Baltimore, MD, USA) IgG antibodies were used for
western blotting. A detailed description of the procedure has been published [21–23]. 3-methy-
ladenine (3MA), rapamycin, MG132, epoxomicin, LY294002 and PD98059 were purchased
from Sigma and Merck Millipore (Merck, Germany). These compounds were dissolved in
dimethyl sulfoxide (Sigma) or deionized distilled water. Monodansylcadaverine (Sigma) was
used as an indicator of autophagolysosomal complexes and dissolved in ethanol (Nacalai Tes-
que, Japan).
Cell cultures
Mouse PrP-overexpressing N2a-58 cells and three lines of these cells persistently infected with
prion strains 22L, Fukuoka-1 or Chandler (N2a-22L, N2a-FK or N2a-Ch), were prepared as
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previously described [23–26]. Briefly, a 10% brain homogenate (BH) was prepared from prion-
disease-onset ddY mice and used to infect N2a-58 cells. All animal experiments were approved
by the Committees on Animal Care and Use of Nagasaki University and were performed
according to their recommendations (Permit No.: 1102170900). The cells were cultured in
DMEM (Sigma) containing 10% heat-inactivated foetal bovine serum and 1% penicillin-strep-
tomycin (Life Technologies, Japan) and split every 3 days at a 5 to 10-fold dilution. All cultured
cells were maintained at 37°C in 5% CO2 in the biohazard prevention area of the author’s insti-
tution. In drug treatment studies, cells (2 × 104 cells/well) were grown in 12-well plate for 24 h
prior to the addition of each drug. In mouse Atg5 knockdown study, psiRNA-mATG5 plasmid
(InvivoGen, USA) was transduced by Fugene 6 (Roche Diagnostics K.K.) as transfectant into
N2a-FK cells and the cells were harvested after 48 h. In knockdown study, psiRNA-Luc GL3
plasmid (InvivoGen) as control was used. Starvation conditions were obtained by replacing the
growth medium with Hank’s balanced salt solution (HBSS; Wako, Japan) and culturing the
cells for 24 h. Fluorescence imaging of autophagic induction was achieved by Lipofectamine
LTX (Life Technologies)-mediated transfection of the cells with plasmid pEGFP-LC3, prepared
by inserting a mouse LC3 cDNA between the BglII and EcoRI sites in the multiple cloning site
(MCS) of pEGFP-C1 (Clontech Laboratories, CA, USA). The plasmid-transfected cells were
treated with the various drugs after 24 h and continuously cultured for 24 h. In autophagic
level evaluation study using immunoblotting and microscope imaging, to inhibit protein degra-
dation in lysosomes, the cells were pre-treated with 10 mMNH4Cl (Nacalai Tesque). After 24
h from NH4Cl treatment, the cells were appropriately added drugs to use for each study and
cultured for a further 24 h.
Western blotting
The drug treated cells were harvested with lysis buffer (50 mM Tris-HCl, pH 7.5, containing
150 mMNaCl, 0.5% Triton X-100, 0.5% sodium deoxycholate and 2 mM EDTA). After 2 min
of centrifugation at 10,000 × g, the supernatant was collected and its total protein concentra-
tion was measured using the BCA protein assay kit (Nacalai Tesque). To detect PrPSc, the pro-
tein concentration was adjusted to 5 mg/ml and the samples were digested with 20 μg
proteinase K (PK; Sigma)/ml at 37°C for 30 min, followed by boiling for 10 min with sample
buffer (50 mM Tris-HCl, pH 6.8, containing 5% glycerol, 1.6% SDS, 100 mM dithiothreitol and
a moderate amount of bromophenol blue). After SDS-polyacrylamide (15%) gel electrophore-
sis, the proteins were transferred onto a PVDF membrane (Immobilon-P; Merck Millipore)
which was blocked with 5% skim milk in TBST (10 mM Tris-HCl, pH 7.8, 100 mMNaCl, 0.1%
Tween 20) for 1 h at room temperature. The membrane was then reacted with diluted primary
(1:1000) and HRP-conjugated secondary antibodies (1:5000). Immunoreactive bands were
visualized by ECL prime (GE Healthcare). To quantify the signals, the intensity of each band
was measured using the NIH image J software. A detailed description of the methods was pre-
viously provided [22].
Lysosomal purification
Lysosomes were purified from mammalian cells as described previously, with several modifica-
tions [27]. All steps were carried out at 4°C unless otherwise noted. Cells at an initial concen-
tration of 1 × 109, corresponding to the number of cells cultured under starvation conditions in
four 75-cm2 flasks, were grown to 90% confluency and harvested by trypsinization. All subse-
quent lysosomal isolation steps were performed according to the protocol included in the lyso-
some isolation kit (Sigma). In brief, the cells were centrifuged at 600 × g for 5 min and
resuspended as a 1mL packed cell volume (PCV) in PBS. After the dilution of 2.7 × PCV mL
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with 1 × extraction buffer, the cells were finally subjected to five freeze-thaw cycles. The degree
of breakage was checked until 80–85% of the cells were broken. Cellular debris such as nuclei
was removed by centrifugation at 2,000 × g for 10 min and the supernatant further was centri-
fuged at 20,000 × g for 1 h. The resulting pellet, containing the crude lysosomal fraction (CLF),
was resuspended in 1 mL of extraction buffer, as the minimal volume. To enrich the lysosomes,
the suspension was further purified by density gradient ultracentrifugation at 150,000 × g for
4 h followed by filling of Diluted Optiprep Fraction (DOF) along with the a part of CLF by 27
to 8% Optiprep Density Gradient Medium solutions, included in the kit, according to the man-
ufacturer’s instructions. After centrifugation, several fractions of the appropriate volume were
collected from the top of the gradient. Each fraction was assayed for the amount of Lamp-1, as
a standard of lysosomal protein, and for β-actin and PrPSc, which was treated with final 40 μg
of proteinase K /ml at 37°C for 30 min.
Immunocytochemistry
The cells were treated with 10 mM 3MA and 1 μM rapamycin, either separately or together, for
24 h or by incubation in HBSS for 8 h, and then incubated with 0.1 mMMDC in PBS for 30 min
at 37°C. The cells were then washed twice with PBS and observed using an Axio Observer Z1
microscope (Carl Zeiss, Deutsch). MDC-positive granules were counted in all treated cells as previ-
ously described [21]. For immunofluorescence analysis, the drug-treated cells were fixed for 20
min at room temperature in 4% paraformaldehyde buffer and permeabilized with 0.5% Triton
X-100 for 5 min at room temperature. For PrPSc staining, the cells were treated with 3M guanidine
thiocyanate for 5 min, blocked for 1 h at room temperature in TBST containing 5% skimmilk and
incubated overnight at 4°C with SAF61 antibody (1:100). The cells were washed in PBS and then
incubated with Alexa Fluor-488-conjugated secondary antibody (Life Technologies) (1:200) for 60
min at 37°C. In this PrPSc detection, prion-uninfected N2a-58 cells as a negative control were used.
For lysosomal staining, the cells were incubated and pre-stained with 1 μMLysotracker dye (Life
Technologies) for 30 min in a CO2 incubator and then fixed as described above. For nuclear stain-
ing, the cells were labelled in mounting medium containing the DNA counterstain DAPI. All
images were obtained using a confocal laser-scanning microscope 700 (Carl Zeiss). The immuno-
fluorescence staining protocols used in this study were previously described in detail [22].
Statistical analysis
Student’s t-test and the Mann-Whitney U-test were used in comparisons of two groups, and
the one-way ANOVA followed by the Tukey-Kramer test in multiple comparisons. The log-
rank test was used to analyse the mortality of prion-infected mice. Statistical analysis of all data
was performed using Statcel 2 of the Excel and GraphPad Prism software.
Results
PrPSc degradation is strongly reduced by lysosomal but not by
proteasomal inhibitors in N2a-FK cells
It is known that protein degradation system can be largely classified into two groups as ubiqui-
tin-proteasome and lysosome system. Thus, to confirm PrPSc degradation system in mouse
neuroblastoma cells persistently infected with a mouse-adapted prion strain derived from a
patient with Gerstmann-Sträussler-Scheinker syndrome, a genetic form of human prion dis-
ease (N2a-FK), we investigated about the degradation pathway using proteasomal and lyso-
somal inhibitors as a familiar pharmacological approach. Treatment of N2a-FK cells with 0.1
to 10 nM epoxomicin or 0.01 to 1 μMMG132, both of which inhibit proteasome activation,
Autophagic Degradation of PrPSc
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had no effect on PrPSc degradation after 48 h (Fig 1A). However, when the cells were treated
with 0.1 to 10 mMNH4Cl, PrP
Sc degradation was inhibited dose-dependently and significantly
(Fig 1A and 1B). These results demonstrate the PrPSc clearance in N2a-FK cells may relate to
the autophagy-lysosomal pathway because it is known that NH4Cl will block the late stage of
the autophagy-lysosomal pathway in lysosomal system.
PrPSc is markedly influenced by inducers and inhibitors of autophagy in
N2a-FK persistently prion-infected cells
To elucidate the detailed degradation mechanism of PrPSc in autophagy-lysosomal pathway,
we analyzed the effects of rapamycin, a widely used macroautophagy activator that inhibits
Fig 1. PrPSc in N2a-FK cells is potently increased by a lysosomal but not by a proteasomal inhibitor. (A) N2aFK cells were treated for 48 h with 0.01 to
1 μMMG132 and 0.1 to 10 nM epoxomicin (Epo) as proteasome inhibitors and 0.1 to 10 mMNH4Cl as a lysosomal inhibitor. PK-treated and-untreated N2a-
FK cells were loaded at concentrations of 100 and 30 μg protein per lane onto a 15% polyacrylamide gel and subjected to SDS-PAGE. The proteins were
detected by western blotting using anti-PrP and -β-actin antibodies. (B) For densitometric analysis, PrPSc band intensities are expressed as a percentage of
those of the negative controls. The results in the graph are the mean ± SD of at least three independent experiments. *p < 0.05 and **p < 0.01 (one-way
ANOVA followed by Tukey's test).
doi:10.1371/journal.pone.0137958.g001
Autophagic Degradation of PrPSc
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mTOR, and 3-methyladenine (3MA), a selective inhibitor of macroautophagy that blocks the
early stage of the autophagy–lysosomal pathway, by inhibiting type-III phosphatidylinositol
3-kinase (PI3K), on PrPSc levels in N2a-FK cells. The cells were treated with 1 to 10 mM 3MA
and 0.2 to 1 μM rapamycin for 48 h. A dose-dependent increment of PrPSc was observed in
N2a-FK cells treated with 3MA and a dose-dependent reduction in those treated with rapamy-
cin (Fig 2 upper). By contrast, neither drug had any effect on PrPSc in mouse neuroblastoma
cells persistently infected with the scrapie-derived 22L or Chandler strain of prions (N2a-22L
and-Ch cells) (Fig 2 middle and bottom).
To determine the level of autophagic activity in N2a-FK cells, we analyzed the expression of
the autophagy-related molecules, LC3-II, Beclin-1 and the Atg12-Atg5 complex. The LC3-II /
LC3-I ratio was 10- to 40-fold higher in rapamycin-treated cells, but was only slightly increased
in 3MA-treated cells. Beclin-1 and Atg12-Atg5 increased in response to rapamycin and
decreased in response to 3MA, both in a dose-dependent manner (S1 Fig). Moreover,
Fig 2. PrPSc in N2a-FK cells is markedly degraded by the autophagy pathway. Persistently prion-infected cells were treated with 1 to 10 mM of
3-methyladenine (3MA) and 0.2 to 1 μM rapamycin (Rap) for 48 h. Proteinase K (PK)-treated N2a-FK, -22L and-Ch cells, which vary in the prion strains, were
loaded at concentrations of 100, 60 and 35 μg protein per lane onto a 15% polyacrylamide gels and subjected to SDS-PAGE. PrPSc was detected by western
blotting using an anti-PrP antibody. For densitometric analysis, the images were scanned and the intensity of each band on the western blotting was
quantified with respect to PrPSc expression levels in drug-treated prion-infected cells, respectively. The results are representative of at least three
independent experiments, with each experiment performed in triplicate. *p < 0.05 and **p < 0.01 (one-way ANOVA followed by Tukey's test).
doi:10.1371/journal.pone.0137958.g002
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rapamycin treatment also caused dose-dependent decreases in phosphorylated S6 ribosomal
protein and phosphorylated eIF4B protein, two markers of the mTOR pathway (S1 Fig). Fur-
thermore, we also investigated about PrPSc degradation using Atg5 shRNA and observed the
increment of PrPSc in N2a-FK cells, indicating that the result of other method was also similar
to that of chemical compound (S2A Fig).
Accordingly, we examined autolysosome, which is the final structure in the autophagy sys-
tem, levels by first altering the autophagic vesicles such that they expressed an EGFP-fused
LC3 transgene and then staining the autolysosomes with the autofluorescent marker mono-
dansylcadaverine (MDC), which specifically detects autolysosomes [28]. LC3-positive vesicles
were increased in N2a-FK cells treated with rapamycin for 24 h, but the increment was sup-
pressed by 3MA (Fig 3A). In previous studies in other mammalian cells, the number of MDC-
positive cells in cultures treated with either oridonin or starvation via amino acid deprivation,
both of which induce autophagy, was reduced by co-treatment with 3MA [28, 29]. As controls
in our study, MDC-labelled vesicles were abundant in N2a-FK cells incubated for 8 h in Hank’s
balanced salt solution (HBSS) to induce starvation, whereas the number of vesicles was signifi-
cantly reduced in starved cells co-treated with 3MA (S3 Fig). Similarly, vesicle induction in
rapamycin-treated N2a-FK cells was strikingly reduced when the cells were co-treated with
3MA for 24 h (Fig 3B). Thus, in our system both rapamycin and starvation strongly induced
autophagy in persistently prion-infected cells.
The localization of PrPSc after autophagy induction was determined by immunofluores-
cence staining of PrPSc in N2a-FK cells treated with the protein denaturant guanidine [30, 31].
In this method, PrPC in N2a-58 prion-uninfected cells were not detected. After 24 h, the accu-
mulation of PrPSc in the cytoplasm was reduced compared to 0 h (Fig 3C). Meanwhile, in rapa-
mycin-treated N2a-22L cells high levels of PrPSc accumulated that strongly localized in the
vicinity of nuclei after 24 h (S4 Fig). In HBSS-starved N2a-FK cells, the reduction of PrPSc was
similar to that of rapamycin-treated cells after 24 h (S5 Fig), indicating that PrPSc might be
selectively degraded by the autophagolysosome system in N2a-FK cells.
The intracellular signalling cascade in the autophagic pathway
contributes to PrPSc clearance in N2a-FK cells
Next, to investigate whether the intracellular signalling cascade of the autophagic pathway had
an effect on the degradation of PrPSc, we tested the effects of PI3K inhibitor, LY294002. The
pharmacological properties of LY294002 include an ability to inhibit the macroautophagic deg-
radation of proteins in mammalian cells at autophagic sequestration step [32, 33] and to block
PI3K-dependent Akt phosphorylation and kinase activity [34, 35]. The effect of LY294002 as a
PI3K inhibitor was confirmed by the dose-dependent decrease in phosphorylated Akt levels in
N2a-FK cells after 48 h (Fig 4A). In similarly treated cells, PrPSc levels significantly and dose-
dependently increased (Fig 4B), confirming the role of PI3K in PrPSc degradation. Next, to
investigate the relationship between PrPSc degradation and the intracellular signalling cascade
downstream of PI3K, we assessed the effects of PD98059, an inhibitor of mitogen-activated
protein kinase/extracellular signal-regulated kinase (MAPK/ERK: MEK), on PrPSc degradation.
MEK signalling regulates autophagy by regulating Beclin-1, through the mTOR pathway [36,
37]. PD98059 inhibits MEK signalling such that the phosphorylation of downstream ERK 1/2
(ERK1/2: P44/P42) is prevented. A role for MEK signalling was verified by the decrease in
phosphorylated MAPK levels in N2a-FK cells (Fig 4A). When these cells were treated with
50 μM of the inhibitor for 48 h, PrPSc levels were significantly increased (Fig 4B). Subsequently,
we asked whether PrPSc degradation by rapamycin-induced autophagy was blocked by these
inhibitors of autophagy-related signalling cascades (Fig 5). Indeed, in N2a-FK cells the
Autophagic Degradation of PrPSc
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Fig 3. Intracellular formation of autophagolysosomes following rapamycin treatment in N2a-FK cells.
(A) To determine autophagic activity in 1 μM rapamycin- or 1 μM rapamycin and 10 mM 3MA-treated N2a-FK
cells, autophagosomes were detected in transfectants expressing the EGFP-fused LC3 gene (inserted into
Autophagic Degradation of PrPSc
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rapamycin-induced decrease in PrPSc was significantly overcome by co-treatment with either
LY294002 (10 μM) or PD98059 (50 μM) for 48 h (Fig 5A). Moreover, the reduction in PrPSc
was significantly recovered in cells co-incubated for 48 h with rapamycin and the lysosomal
inhibitor NH4Cl (Fig 5B). These results provide evidence of the involvement of PI3K and MEK
signalling in autophagy-mediated degradation of PrPSc in N2a-FK cells.
Nearly all of the PrPSc in N2a-FK cells is degraded in lysosomes
Autophagolysosomes are the product of autophagosome and lysosome fusion and their forma-
tion is a necessary step in protein clearance by the autophagy system. In HBSS-starved N2a-FK
cells, the accumulation of PrPSc was co-localized in lysosomes in the vicinity of nuclei after 8 h,
and the PrPSc was reduced after 24 h like rapamycin treatment (Fig 3C and S5 Fig). To confirm
the localization of PrPSc within the lysosomal fraction after autophagic induction, we followed
the subcellular localization of PrPSc and the lysosomal marker Lamp1 in N2a-FK cells by isolat-
ing a pure lysosomal fraction. Under control conditions, PrPSc localized to the same lysosome-
rich fractions as Lamp1 (Fig 6A, left, lanes 1 to 3). However, in N2a-FK cells in which autop-
hagy was induced by starvation conditions (8 h of HBSS treatment), although total PrP, Lamp1
and β-actin band intensities were similar, there was little PrPSc in the Lamp1 fractions (Fig 6A,
right, lanes 1 to 3). Quantification of the ratio of PrPSc in each fraction (F1 to F4), based on
band intensity, showed significantly less PrPSc in the lysosome-rich fractions (F1 and F2) of
HBSS-starved cells treatment than in those of control cells (Fig 6B), suggesting that under nor-
mal conditions PrPSc might be almost completely degraded in the lysosomal fraction, via the
autophagic system.
Discussion
In this study, PrPSc in N2a-FK cells was degraded by an autophagic process enhanced by the
inducer rapamycin. By contrast, rapamycin had no effect on PrPC in N2a-58 cells (S2B Fig),
indicating that autophagy might be one of the degradation system involved in PrPSc but not in
PrPC degradation. Recently, Xu Y, et al. reported that scrapie-derived PrPSc is degraded by
mTOR-related autophagic system via FBXW7 protein [38]. It is possible that GSS-derived
PrPSc may also relate to the degradation system mediating FBXW7, but the elucidation of its
option will need to be further investigated.
The site-specific proteolysis of LC3-I (18 kDa) to LC3-II (16 kDa) is indicative of autophagic
activity, as are Beclin-1 and the Atg12-Atg5 complex. The latter are required for nucleation of
the phagophore and maturation of the autolysosome in mediating autophagosome formation.
In our study, LC3 activation in rapamycin-treated N2a-FK cells was approximately 40-fold
stronger than in non-treated control cells (S1 Fig). Rapamycin also increased the levels of
Beclin-1 and the Atg12-Atg5 complex, both of which were reduced by 3MA treatment, and
plasmid pcDNA 3.1) and the morphological changes in LC3-positive granular vesicles were followed. (B)
Autophagolysosomes in cells treated with 1 μM rapamycin for 24 h were visualized using 0.1 mM of
monodansylcadaverine (MDC) for 30 min (left, three panels per group). To inhibit rapamycin-induced
autophagy, N2a-FK cells were co-treated with 10 mM 3MA. Scale-bars represent 10 μm. To quantify the
average number of MDC-labeled autolysosomes in a single cell, the vesicles in the treated cells were shown
as a graph represented by the mean ± SD of three independent experiments (right). **p < 0.01 (one-way
ANOVA followed by Tukey's test). (C) N2a-FK cells treated with 1 μM rapamycin for 24 h were pre-treated
with 3 M guanidine thiocyanate prior to the antibody reaction. PrPSc in cells was detected using the SAF61
antibody (green) and N2a-58 cells were stained as a negative control. Cell nuclei were counterstained with
DAPI (blue). The cells were visualized by confocal laser scanning microscopy. Differential interference
contrast (DIC) images were obtained to confirm the consistency of the experimental condition. Scale-bars
represent 10 μm.
doi:10.1371/journal.pone.0137958.g003
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decreased markers of the mTOR signalling as phosphorylated S6 ribosomal protein and phos-
phorylated eIF4B protein (S1 Fig). It already have been confirmed that expression of Beclin1
Fig 4. PrPSc in N2a-FK cells undergoes degradation via upstream intracellular signalling cascades associated with autophagy. (A) N2a-FK cells
were treated with 0.1 to 10 μM of the the PI3K inhibitor LY294002 and 1 to 50 μM of the MEK inhibitor of PD98059 for 48 h. PK-treated or-untreated samples
were applied at concentrations of 100 and 50 μg protein per lane onto a 15% polyacrylamide gel and subjected to SDS-PAGE. The proteins were analyzed
by western blotting using anti-PrP, anti-Akt, anti-phosphorylated Akt (to determine the Akt activation level), anti-p44/p42 MAPK, anti-phosphorylated p44/p42
MAPK (to determine the p44/p42 MAPK activation level) and anti-β-actin antibodies. (B) The effect of these drugs on PrPSc was determined by quantifying
the PrPSc band intensities as a percentage of those of the negative controls. The results in the graph are the mean ± SD of at least three independent
experiments. *p < 0.05 and **p < 0.01 (one-way ANOVA followed by Tukey's test).
doi:10.1371/journal.pone.0137958.g004
Autophagic Degradation of PrPSc
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and Atg5 were increased by starvation-induced activation of cardiac autophagy in mice and
that of neonatal mice to supply the amino acids for energy homeostasis [39, 40]. In N2a-FK
cells, some autophagy-related proteins also may be produced by the same mechanism after
autophagic activation. However, the detailed mechanism remains to be determined. These
results indicate that PrPSc in N2a-FK cells might be degraded by the canonical autophagic sys-
tem, which is induced by rapamycin.
In autophagic signalling, LY294002 specifically blocks PI3K-dependent Akt phosphoryla-
tion and kinase activity, resulting in a drastic inhibition of autophagy [32–35]. In another
Fig 5. Effects of PI3K, MEK and lysosomal inhibitors on rapamycin-elicited autophagic responses in N2a-FK cells. (A) N2a-FK cells were co-treated
with LY294002 (10 μM) or PD98059 (50 μM) along with rapamycin (1 μM) for 48 h. (B) N2a-FK cells were co-treated with NH4Cl (10 mM) together with
rapamycin (1 μM) for 48 h. Upper: PK-treated or-untreated samples were applied at concentrations of 100 and 50 μg protein per lane onto a 15%
polyacrylamide gel and subjected to SDS-PAGE. The proteins were detected by western blotting using anti-PrP,-LC3 and -β-actin antibodies. Bottom: PrPSc
expression levels following drug treatment were quantified in N2a-FK cells. The results are representative of at least three independent experiments, with
each experiment performed in triplicate. *p < 0.05 and **p < 0.01 (one-way ANOVA followed by Tukey's test).
doi:10.1371/journal.pone.0137958.g005
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Fig 6. PrPSc levels in the lysosomal fraction are reduced following autophagy in starved cells. (A)
Lysosomes were isolated by the fractionation of N2a-FK cells incubated or not in HBSS for 8 h, as an inducer
of autophagy. PK-treated or-untreated gradient fractions were applied at one-tenth of their original volume per
lane onto a 15% polyacrylamide gel and subjected to SDS-PAGE. The proteins were detected by western
blotting using anti-PrP, anti-Lamp1 (as a lysosomal marker) and anti-β-actin (as the internal standard)
antibodies. Fractions 1 to 3 contained high-quality, purified native lysosomes. Positive controls consisted of
cell lysates containing 15 μg of protein before purification (P). (B) To quantify ratio of the PrPSc degradation in
the isolated lysosomes, PrPSc band intensities were measured as a percentage of those of the controls.
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study, the activation of autophagy by HBSS was more strongly prevented by LY294002 than by
wortmannin, another inhibitor of PI3K [37]. Here we showed that PrPSc levels in N2a-FK cells
are regulated by an autophagic system involving PI3K and MEK signalling (Figs 4 and 5). In
Beclin-1-dependent autophagic activation, an important pathway is that in which Bcl2 is phos-
phorylated by phosphorylated ERK. In HBSS-starved cells, phosphorylated ERK is suppressed
by PD98059 via the inhibition of P44/P42 MAPK, and autophagic sequestration is prevented
by increment of Beclin-1 and unphosphorylated Bcl2 complex [37]. In autophagic sequestra-
tion inhibitory system by nitric oxide (NO), disruption of hVps34/Beclin-1 complex formation
is leaded by increment of Beclin-1/Bcl2 interaction after phosphorylated Bcl2 reduction due to
inhibition of JNK1 by NO [41]. It is furthermore likely that PD98059 inhibits autophagy via
MAPK-regulated mTOR signalling [42]. Thus, the mechanism underlying the autophagic deg-
radation of PrPSc in N2a-FK seems to involve a pathway that includes mTOR, PI3K and MEK
signalling.
In this study, we were not able to find the evidence of the autophagic degradation of PrPSc
in N2a-Ch and N2a-22L cells, whereas it has reported that PrPSc in RML-inefcted N2a cells sig-
nificantly reduced after rapamycin treatment [17, 19]. Likewise, we previously reported that
PrPSc in N2a-FK cells was degraded by autophagy in a process activated by FK506 (tacrolimus)
[21], while Karapetyan et al. showed that tacrolimus reduces PrPSc in RML-infected cells in the
absence of autophagic activation [43]. According to Kawasaki et al., compound-B strongly
reduces PrPSc of the RML strain but had only marginally effects on prion strains 22L and FK-1
[44]. These results raise the question, why does the degradation of PrPSc differ for each prion
strain? A difference in the biochemical properties of PrPSc from different strains such that they
differ in their sensitivity to proteolytic enzymes is unlikely because there is no difference in the
conformational stabilities of PrPSc in N2a-22L and-FK cells following their denaturation by
guanidine hydrochloride [45]. It was previously reported that low-dose and long-term treat-
ment of 22L- and RML-prion infected GT-1 cells with rapamycin reduces PrPSc levels, by sup-
pressing protein translation [46]. However, similar experiments were beyond the scope of this
study. Evidence of alternative pathways of PrPSc degradation comes from a study showing that
both tamoxifen and 4-hydroxytamoxifen decrease PrPSc in an autophagy-independent manner,
by bringing PrP to lysosomes [47], indicating that the degradation mechanism of PrPSc might
have various pathway. Thus, these verification need to be further examined using various prion
strains.
In summary, our results demonstrated that PrPSc in Fukuoka-1 prion strain-derived cells
might be efficiently degraded in canonical autophagic system-dependently compared with
those in other prion strains-derived cells. This finding indicates that we might have to alter the
therapeutic strategies by patients with Creutzfeldt-Jakob disease, and suggests the need for new
therapeutic strategies, such as the use of autophagy-inducing compounds, in patients with
Gerstmann-Sträussler-Scheinker syndrome. Further studies of the autophagy-mediated degra-
dation of PrPSc will provide additional therapeutic insights and the necessary advances to one
day allow the complete cure of prion diseases.
Supporting Information
S1 Fig. The effect of autophagy-related proteins in N2a-FK cells after 3MA and rapamycin
treatment. N2a-FK cells were treated with 1 to 10 mM of 3-methyladenine (3MA) and 0.2 to
Empty columns indicate the control, non-treated fractions and shaded columns the HBSS-treated fractions.
The results in the graph are the mean ± SD of at least three independent experiments. *p < 0.05 (Student's t-
test).
doi:10.1371/journal.pone.0137958.g006
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1 μM rapamycin (Rap) for 48 h. PK-untreated samples containing 10 to 30 μg of protein were
used to investigate the expression of total PrP, LC3, Beclin-1 and the Atg12-Atg5 complex as
indicators of autophagic flux. To confirm the levels of autophagy, LC3-II/-I ratio was assessed
by LC3 blotting. β-actin was used as the internal standard for each sample. Phosphorylated S6
ribosomal protein (Ser235 and Ser236) (p-S6) and phosphorylated eIF4B protein (Ser422) (p-
eIF4B) levels, as indicators of a rapamycin effect, were performed with western blotting.
(EPS)
S2 Fig. The effect of mAtg5 shRNA in prion-infected cells and that of 3MA and rapamycin
in prion–uninfected cells. (A) N2a-FK cells which were transduced with mouse Atg5
(mATG5) or Luc-GL3 shRNA plasmids were harvested after 48 h. The psiRNA Luc-GL3 plas-
mid was used as control. The PrPSc, Atg12-Atg5 complex and β-actin were detected by western
blotting and PrPSc levels were quantified in the cells. (B) PK-untreated samples in N2a-58
prion-uninfected cells which treated with 3MA and Rap for 48 h were used 40 μg protein per
lane, and investigated PrPC expression in drug-treated cells using immunoblotting. PrPC levels
were quantified in the cells. The results are representative of at least three independent experi-
ments, with this experiment performed in triplicate.
(EPS)
S3 Fig. MDC staining for autophagolysosome detection following HBSS treatment in N2a-
FK cells. Autophagolysosomes in cells treated with HBSS for 8 h were visualized using 0.1 mM
of monodansylcadaverine (MDC) for 30 min (left, three panels per group). Right panels show
inset images. To inhibit HBSS-induced autophagy, N2a-FK cells were co-treated with 10 mM
3MA. Scale-bars represent 10 μm. To quantify the average number of MDC-labeled autolyso-
somes in a single cell, the vesicles in the treated cells were shown as a graph represented by the
mean ± SD of three independent experiments (right). p< 0.01 (one-way ANOVA followed
by Tukey's test).
(EPS)
S4 Fig. PrPSc in the N2a-22L cells were not reduced by autophagy triggering rapamycin
treatment. The rapamycin-treated the N2a-22L cells were pre-treated with 3M guanidine thio-
cyanate, prior to antibody reaction. PrPSc was detected by SAF61 antibody (green). Cell nuclei
were counterstained with DAPI (blue). All images were visualized by CLSM700. The differen-
tial interference contrast (DIC) images were demonstrated to confirm the consistency in all
experimental condition. Scale-bars represent 10 μm.
(EPS)
S5 Fig. Intracellular localization of PrPSc following HBSS-induced autophagy in prion-
infected cells. PrPSc was analyzed in N2a-FK cells treated with HBSS. The cells were visualized
by confocal laser scanning microscopy. Differential interference contrast (DIC) images were
obtained to confirm the consistency of the experimental condition. Scale-bars represent 10 μm.
(EPS)
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